Helmut Oettle, M.D., Ph.D., of the Charite - Universitatsmedizin Berlin, Germany, and colleagues conducted follow - up of a randomized trial that previously reported improvement in disease - free survival with adjuvant (in addition to surgery)
gemcitabine therapy to determine if this treatment improved overall survival.
Not exact matches
The researchers report that these two
therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard
therapy or following administration of either brentuximab vedotin or
gemcitabine alone.
The research team evaluated the combination of the biologic
therapy brentuximab vedotin (Adcetris), a monoclonal antibody - drug conjugate, with the chemotherapy drug
gemcitabine (Gemzar) in 42 pediatric and young - adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.
The findings suggest that
therapies combining these microRNAs and
gemcitabine could improve our ability to treat pancreatic cancer, and measurement of microRNA levels could also provide a guide to the prognosis in such cases.
All but one of the ten patients transitioned to treatment with
gemcitabine, which is a standard
therapy for pancreas cancer.
«The finding provides a strong rationale for combination
therapy with pemetrexed and
gemcitabine for treatment of group 3 medulloblastoma,» Roussel said.
Inclusion Criteria: • The participant may have no more than 2 prior lines of systemic
therapies (neoadjuvant and adjuvant
therapies will not be considered as a prior line of
therapy) for advanced or metastatic disease and is suitable to receive
gemcitabine and docetaxel
therapy.